This clinical trial is focused on studying the disease known as Monkeypox virus disease, which is sometimes referred to as mpox. The study involves a treatment using a medication called Tecovirimat, which is taken in the form of 200 mg hard capsules. The purpose of the study is to observe the clinical outcomes in patients with mpox who are treated with tecovirimat or other antiviral drugs, as well as those who are not treated with these medications.
Participants in the study will be monitored over a period of time to see how their condition progresses. The study will look at how quickly the skin lesions caused by the mpox virus heal, starting from the date of a positive test or the beginning of treatment, and continuing for up to 14 days. The study will also assess the overall health status of participants on days 14 and 28, and check for any signs of the disease returning on days 60 and 180. Additionally, the study will monitor the levels of mpox virus DNA in the throat, blood, and lesion swabs at various points during the study.
For those receiving tecovirimat or other antiviral treatments, the study will track any serious side effects or unexpected reactions within 28 days of starting the study. The study will also consider the outcomes for pregnant women who are participating. This research aims to provide valuable information on the effectiveness and safety of tecovirimat and other antiviral treatments for mpox.
Belgium 
France 
Ireland 
Italy 
Norway 
Portugal 
Spain 
The Netherlands